2022
Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia
Bazazi A, Culbert G, Wegman M, Heimer R, Kamarulzaman A, Altice F. Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia. BMC Infectious Diseases 2022, 22: 837. PMID: 36368939, PMCID: PMC9652918, DOI: 10.1186/s12879-022-07804-6.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyInfectious etiologyMost deathsUse disordersSample of menPrison releaseOpen-label trialT-lymphocyte countsPredictors of mortalityNational death recordsCrude mortality rateProportional hazards modelCovariate-adjusted modelsLow CD4Methadone initiationModified intentionAgonist therapySurvival benefitTreat analysisMethodsThis studyHIVHazards modelMortality rateMethadone
1995
Zygomycosis (Mucormycosis) and HIV Infection: Report of Three Cases and Review
Nagy-Agren S, Chu P, Smith G, Waskin H, Altice F. Zygomycosis (Mucormycosis) and HIV Infection: Report of Three Cases and Review. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1995, 10: 441-449. PMID: 7583440, DOI: 10.1097/00042560-199512000-00007.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAIDS patientsBasal gangliaAdvanced HIV diseaseSite of involvementCases of zygomycosisInjection drug usersSite of diseaseIntravenous amphotericinLow CD4Renal zygomycosisFulminant courseHIV diseaseLymphocyte countSurgical debridementHIV infectionOverall mortalityOpportunistic infectionsImmunodeficiency virusCase reportRisk factorsRespiratory tractSuccessful therapyZygomycosisTransient episodes